Medical Doctor Program year 2021 Source: CMS Open Payments, 2026 publication

Ho-Yann Jong

Neurology Portland, OR Medical Doctor

NPI 1699096610 CMS profile 1264711

9135 Sw Barnes Rd Ste 461, Portland, OR 97225

Open in the dashboard

General payments

$0

None reported · program year 2021

Research payments

$3,006

Paid to them · 1 record reported · program year 2021

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,522 paid to institutions, not to them · program years 2019–2021

Through program year 2021, Ho-Yann Jong of Portland, OR is reported in the CMS Open Payments database as having received $0 across 0 general payments and $3,006 in research payments paid to them. Separately, studies naming them as principal investigator received $7,522 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 59th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2021 Research $3,006 1

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

1,786

Median for Neurology: 833

Drug cost

$38,325

Median for Neurology: $202,670

Branded share of claims

10.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Memantine Hcl Generic 550 $12,421
Galantamine Er Galantamine Hbr Brand 157 $10,968
Donepezil Hcl Generic 953 $8,634
Rivastigmine Generic 34 $5,265
Rivastigmine Rivastigmine Tartrate Brand 17 $425
Sertraline Hcl Generic 48 $334
Carbidopa-Levodopa Carbidopa/Levodopa Brand 13 $228
Quetiapine Fumarate Generic 14 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$76,219

Medicare's payments for the services billed

Medicare patients

334

Average age 76

Services billed

653

174 women, 160 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Alzheimer's or dementia 69%
High blood pressure 62%
Arthritis 39%
Depression 36%
Diabetes 26%
Atrial fibrillation 19%
Chronic kidney disease 19%
Ischemic heart disease 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record